Atherosclerosis-targeted liposome nanocarrier delivery system and preparation method therefor
US-2024424132-A1 · Dec 26, 2024 · US
Pharmaceutical composition for preventing or treating coronavirus disease-19
US12544360B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12544360-B2 |
| Application number | US-202117625327-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 27, 2021 |
| Priority date | Apr 29, 2020 |
| Publication date | Feb 10, 2026 |
| Grant date | Feb 10, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a pharmaceutical composition for preventing or treating coronavirus disease 2019, and more specifically to a pharmaceutical composition for preventing or treating coronavirus disease 2019 found by drug repositioning technology using drug virtual screening technology. The pharmaceutical composition for preventing or treating coronavirus disease 2019 according to the present invention is a composition obtained by finding new uses for drugs, which have already been proven effective, for preventing or treating coronavirus disease 2019 by drug repositioning technology. The pharmaceutical composition is useful because it has significantly lower side effects than new drugs and can be rapidly applied to clinical practice.
First claim
Opening claim text (preview).
What is claimed is: 1 . A method of preventing or treating coronavirus disease 2019 (COVID-19) in a subject in need thereof, comprising: administering tipifarnib; and administering one or more compounds selected from the group consisting of omipalisib, blonanserin, emodin, and remdesivir. 2 . The method of claim 1 , comprising administering blonanserin, wherein the tipifarnib is administered at a concentration of 2.75 μM to 11 μM, and the blonanserin is administered at a concentration of 1.50 μM to 47.87 μM. 3 . The method of claim 1 , comprising administering emodin, wherein the tipifarnib is administered at a concentration of more than 0 μM and not more than 11 μM, and the emodin is administered at a concentration of 1.97 μM to 31.45 μM. 4 . The method of claim 1 , comprising administering omipalisib, wherein the tipifarnib is administered at a concentration of 1.38 μM to 11 μM, and the omipalisib is administered at a concentration of 0.25 μM to 1.97 μM; or the tipifarnib is administered at a concentration of more than 0 μM and not more than 11 μM, and the omipalisib is administered at a concentration of more than 0 μM and not more than 0.25 μM. 5 . The method of claim 1 , comprising administering remdesivir, wherein the remdesivir is administered at a concentration of more than 0 μM and not more than 20.18 μM, and the tipifarnib is administered at a concentration of more than 0 μM and not more than 11 μM.
Assignees
Inventors
Classifications
not condensed and containing further heterocyclic rings · CPC title
- A61K31/4709Primary
Non-condensed quinolines and containing further heterocyclic rings · CPC title
having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin · CPC title
for RNA viruses · CPC title
ortho- or peri-condensed with heterocyclic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12544360B2 cover?
- The present invention relates to a pharmaceutical composition for preventing or treating coronavirus disease 2019, and more specifically to a pharmaceutical composition for preventing or treating coronavirus disease 2019 found by drug repositioning technology using drug virtual screening technology. The pharmaceutical composition for preventing or treating coronavirus disease 2019 according to …
- Who is the assignee on this patent?
- Korea Advanced Inst Sci & Tech, Pasteur Institut Korea
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4709. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 10 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).